Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations [2]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 4, 2005, Pages 796-797

  O'Brien, L A ^a   Sutherland, J J ^a   Weaver, D F ^b   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENT RECEPTOR; GLYCOPROTEIN; INTEGRIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; POLYMER; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CRYSTAL STRUCTURE; DISULFIDE BOND; GENE MUTATION; HEMOSTASIS; LETTER; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; SHEAR STRESS; THROMBOCYTE; VON WILLEBRAND DISEASE; X RAY CRYSTALLOGRAPHY; GENETICS; HUMAN; MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN TERTIARY STRUCTURE;

HUMANS; MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 23044513630     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01219.x     Document Type: Letter

References (7)

1. Lyons SE, Cooney KA, Bockenstedt P, Ginsburg D. Characterization of Leu777Pro and Ile865Thr type IIa von Willebrand disease mutations. Blood 1994; 83: 1551-7.
2. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIa von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
3. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood 1998; 91: 2032-44.
4. Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 2004; 10: 259-70.
5. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-9.
6. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
7. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-12.